Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047827 · ClinicalTrials.gov registry record · Phase 2
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00047827 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 2 participants.
The verdict
NCT00047827, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
Interventions
- DRUG Micafungin
- DRUG Liposomal Amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047827
The ClinicalTrials.gov registry entry for NCT00047827 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Micafungin is the first listed.
NCT00047827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047827 about?
NCT00047827 is a clinical study titled "Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis". The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
What is the current status of trial NCT00047827?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2002-12. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00047827?
The interventions under investigation include: Micafungin (DRUG), Liposomal Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00047827?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.